Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2023-06-06 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly report detailing changes in the company's share capital and issued shares, including stock options and other share issuance arrangements. It is addressed to the Hong Kong Stock Exchange and references compliance with the Listing Rules Chapter 19B. The document includes detailed tables of share movements, confirmations of board authorization, and compliance with listing conditions. It is not an annual or interim financial report, nor an earnings release or management discussion. It is a regulatory filing specifically reporting share capital changes and share issuance activities for the month ending May 31, 2023. The document length is 4627 characters, which is substantive and contains detailed data, not just an announcement or certification. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2023-06-06 Chinese
港股公告：授出购股权及受限制股份单位
Regulatory Filings Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the grant of share options and restricted share units under the 2016 Option and Incentive Plan. It details the number of shares/options granted, exercise prices, vesting schedules, and related terms. The text references compliance with listing rules and provides definitions related to the share plan. There is no financial statement or comprehensive financial analysis present. The document is a regulatory announcement about equity compensation grants to employees, not a full report or financial filing. It fits the category of a Regulatory Filing (RNS) as it is a compliance announcement related to share-based compensation under listing rules, without being a full report or a simple notice of dividend or capital change. The document length is 3531 characters, which is relatively short and consistent with an announcement rather than a full report.
2023-06-06 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance and repurchase data, dates, share prices, and percentages. It also contains formal confirmations by the company's executive director and CEO regarding the authorization and compliance of the share issuance. The document length is 3765 characters, which is relatively short but contains substantive data on share capital changes rather than just an announcement of a report. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2023-06-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company, referencing specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It includes data on share issuance, share counts before and after issuance, share prices, and related authorizations by the board. The document is not an announcement of a report but the actual disclosure itself, containing substantive data on share capital changes. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or other capital changes. The document length is 4927 characters, sufficient to contain detailed data rather than a brief announcement. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2023-05-31 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Listing Rule 13.25A and GEM Listing Rule 17.27A) which require disclosure of changes in issued share capital. The document details share issuance under a share award plan, share counts before and after issuance, and includes a formal confirmation by the company's executive director and CEO. There is no indication of this being a full financial report, earnings release, or management discussion. The content is focused on share capital changes and disclosures required by the exchange rules. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is about 4920 characters, which is sufficient to contain substantive disclosure rather than a mere announcement or certification, so it is not an RPA or RNS filing.
2023-05-29 Chinese
百济神州有限公司自愿披露关于在2023年美国临床肿瘤学会（ASCO）年会展示最新临床数据的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. about presenting the latest clinical data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. It details clinical trial results and early research data for several drugs but does not contain comprehensive financial statements or detailed financial performance data. The document is relatively short (2528 characters) and serves as an update on clinical progress and potential risks rather than a full report. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing or certification. The content is primarily an announcement of clinical data presentation at a conference, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2023-05-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.